

National Institutes of Health Update

Claire Schuster, MPH
National Institute of Allergy and Infectious Diseases
National Institutes of Health

December 2020




1

mRNA-1273 Vaccine in Older Adults

THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E.J. Anderson, N.G. Rouphael, A.T. Widge, L.A. Jackson, P.C. Roberts, M. Makhene, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A. Doria-Rose, S. O'Dell, S.D. Schmidt, K.S. Corbett, P.A. Swanson II, M. Padilla, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V.V. Edara, K. Floyd, M.S. Suthar, D.R. Martinez, R. Baric, W. Buchanan, C.J. Luke, V.K. Phadke, C.A. Rostad, J.E. Ledgerwood, B.S. Graham, and J.H. Beigel, for the mRNA-1273 Study Group*



2

Selected COVID-19 Vaccine Candidates

Platform	Developer	Phase 1/2	Phase 2/3
Nucleic acid	 moderna	Enrolled	Ongoing
	 BIONTECH	Enrolled	Ongoing
Viral vector	 UNIVERSITY OF OXFORD	Enrolled	Ongoing
	 AstraZeneca	Enrolled	Ongoing
	 janssen	Enrolled	Ongoing
Protein subunit	 MERCK	Ongoing	--
	 NOVAVAX	Ongoing	Ongoing
	 esk	Ongoing	--
	 SANOFI	Ongoing	--

AS Fauci/NIID
National Institute of Allergy and Infectious Diseases

Updated: November 6, 2020



3

ACTIV 1-4

- ACTIV-1:** An adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19 (infliximab, abatacept, Cenicriviroc).
- ACTIV-2:** An outpatient Phase 2 clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies to treat the disease.
- ACTIV-3:** An inpatient Phase 3 randomized, controlled trial that provides a "master protocol" to test multiple different kinds of monoclonal antibody treatments. *(Sub-study closed on Oct. 26)*
- ACTIV-4:** A "master protocol" to evaluate the safety and effectiveness of different types of blood thinners to treat patients with diagnosed COVID-19.

ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)




4

ACTIV-5/Big Effect Trial



NIH Study Aims To Identify Promising COVID-19 Treatments for Larger Clinical Trials

October 13, 2020



Scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab.
Credit: NIAID



5

Acute Flaccid Myelitis Update

NIAID Awards Contract to Develop Enterovirus-D68 Vaccine

- Growing concerns about global spread of this respiratory enterovirus
- NIAID awarded contract to Intravacc for development of inactivated EV-D68 vaccine candidate
- Vaccine aims to protect children from Acute Flaccid Myelitis (AFM)



6

NIAID Now Blog

Childhood Pneumonia Study Shows Short-Course Antibiotics Superior to Standard of Care



- NIAID-sponsored randomized, double-blind, placebo-controlled trial
- 5 day antibiotic treatment is superior to standard (10 day) treatment of community-acquired pneumonia (CAP) in children 6 months to 5 years.

 National Institute of Allergy and Infectious Diseases

7

NIH Updates

NIH Director's Blog

Search This Blog

Speeding COVID-19 Drug Discovery with Quantum Dots

COVID-19 Update

Recent Posts

- COVID-19 Update: Masks
- COVID-19 Update: Drug Targets

A Q&A on COVID-19 Vaccine Research

 National Institute of Allergy and Infectious Diseases

8